Podcasts about therapies

How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung cancer patient's treatment plan? In this episode of the 2025 NSCLC Creator Weekend™ series, our tumor board discusses the complexities of lung cancer treatment, including new systemic therapies, lung cancer staging, and the role of molecular diagnostics and liquid biopsies. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS The panel, featuring specialists from various institutions, discusses the specifics of sequencing therapies, the impact of targeted and immunotherapies, and the nuances of treating different patient profiles, including non-smokers and those with specific genetic mutations. The conversation also touches on the integration of new staging systems, the benefits of multidisciplinary clinics, and the ongoing evolution of cancer treatment trials. The discussion aims to provide clarity on the latest advancements and future directions in managing lung cancer, emphasizing the importance of tailored treatment plans and the potential of emerging technologies. --- TIMESTAMPS 00:00 - Introduction05:16 - Molecular Diagnostics and Liquid Biopsy21:43 - Targeted Therapy Options27:29 - Managing Toxicities and Treatment Strategies33:13 - Challenges with Immunotherapy in Special Cases34:07 - Lung Transplantation in Cancer Patients48:38 - Multidisciplinary Clinics and Collaboration01:06:29 - Future Directions --- RESOURCES ADAURA Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2027071 Gomez NSCLChttps://pmc.ncbi.nlm.nih.gov/articles/PMC5143183/

Dermatomyositis is a rare multi-organ autoimmune condition that primarily affects the skin and muscles. It causes fatigue, muscle weakness, and painful skin rashes. Treatment for the condition has long centered on the use of chronic systemic steroids, which can carry long‑term toxicity. Priovant is developing brepocitinib, a dual TYK2/JAK1 inhibitor originally developed at Pfizer to treat the condition. We spoke to Ben Zimmer, CEO of Priovant, about the company's experimental targeted therapy to treat dermatomyositis, how its relationship with its parent Roivant frees it from reliance on the capital markets, and the broader potential of n the treatment.

Send us a textIn this episode, Dr. Andrew Beverstock discusses his research on urinary sodium and its relationship with growth in preterm neonates. He shares insights into the importance of sodium for neonatal growth, the methodology of his study, and the unexpected results that challenge existing literature. The conversation also touches on his diverse medical training, mentorship experiences, and his involvement in medical education and point-of-care ultrasound (POCUS). Dr. Beverstock emphasizes the significance of careful population selection in research and outlines his future research directions. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Blunt Business speaks with Joel Latham, CEO of Incannex Healthcare (NASDAQ: IXHL), a clinical-stage biopharmaceutical company pioneering the use of proprietary combination medicines. Latham breaks down their strategy of fusing synthetic cannabinoids and well-characterized active drug components to target chronic conditions with significant unmet needs, emphasizing a robust intellectual property position and synergistic drug action.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore the latest advances and strategic moves shaping the industry, providing you with insights into how these developments might influence drug development and patient care.The pharmaceutical and biotech sectors are currently experiencing a wave of transformative changes. A significant development is the trade agreement between the United States and the United Kingdom, which excludes medicines from import tariffs. This strategic move, orchestrated by the Trump administration, is set to reduce costs and bolster investments in pharma sectors across both nations. By enhancing market accessibility, it aims to stimulate cross-border investment in pharmaceutical research and production.On the clinical front, Eli Lilly is making headlines by joining Novo Nordisk in reducing self-pay prices for its GLP-1 receptor agonist, Zepbound. This reflects a broader industry trend towards patient-centric pricing models aimed at improving affordability. With healthcare costs on the rise, these measures could ease financial burdens for patients requiring long-term medication regimens.Regulatory updates are also making waves, with the FDA planning stricter vaccine regulations under Dr. Vinay Prasad's leadership at the Center for Biologics Evaluation and Research (CBER). These updates come amid concerns over vaccine safety during COVID-19-related incidents, underscoring a commitment to maintaining public trust in vaccines. Regulatory scrutiny continues as Prasad focuses on COVID-19 vaccine safety in children amid reports linking 10 child deaths to vaccines via VAERS—emphasizing challenges interpreting safety data while highlighting the need for robust methodologies ensuring reliable causality conclusions.In corporate restructuring news, Valneva is streamlining its operations by closing a site and eliminating 30 roles. This move highlights an industry focus on optimizing resources to bolster vaccine development pipelines. Meanwhile, Microsize and Schedio's acquisition of Lonza's Swiss micronization plant underscores ongoing investments in advanced manufacturing technologies critical for high-quality pharmaceuticals.In ophthalmology, Belite Bio is advancing with promising Phase 3 results for tinlarebant in treating Stargardt disease—a rare genetic eye disorder. This success positions Belite to file for FDA approval, potentially expanding treatment options for this underserved patient population. Such advancements in targeted therapies emphasize the need for ongoing research in genetic disorders.Regeneron is betting $150 million on Tessera's gene writing technology targeting alpha-1 antitrypsin deficiency (AATD). This collaboration highlights the industry's growing interest in gene therapy as a frontier for treating rare diseases, marking a shift towards precision medicine where tailored genetic interventions offer hope for previously untreatable conditions. Regeneron's strategic move investing $275 million partnering with Tessera exploring gene editing capabilities—focusing on TSRA-196 targeting the SERPINA1 gene linked to AATD showcases potential advancing therapeutic options for genetic disorders through gene editing technologies offering new disease treatment avenues.AI-driven platforms were spotlighted at RSNA 2025 by industry leaders such as GE Healthcare, Philips, and Siemens. These innovations promise to revolutionize radiological workflows by enhancing diagnostic accuracy and operational efficiency through AI integration. As AI continues to permeate healthcare technologies, its potential to transform diagnostic processes marks a significant leap towards personalized medicine.Akebia Therapeutics' acquisition ofSupport the show

Is your patient's proteinuria low enough? New KDIGO goals: target the immune cause and hit < 0.5 g/day to preserve kidney function.   Credit available for this activity expires: 12/2/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003055?ecd=bdc_podcast_libsyn_mscpedu

Dr. Ian Winship is an Associate Professor and a former Alberta Innovates Health Solutions Scholar in the Department of Psychiatry at the University of Alberta. He is also Director of the Neurochemical Research Unit there. Ian is interested in understanding how we can reduce the damage early after a stroke and ways we can improve recovery in people who had a stroke a long time ago. His research also examines changes in the brain that lead to symptoms in other brain disorders like schizophrenia. Much of Ian's free time is spent on or near the ice rink. He coaches his son's hockey team and his daughter's ringette team, as well as playing on his own recreational hockey team. In the summer, Ian enjoys being outside, traveling, visiting the mountains, and relaxing at the beach. Ian received his bachelor's and doctoral degrees in Psychology from the University of Alberta. Afterwards, he conducted postdoctoral research at the University of British Columbia before returning to the University of Alberta to join the faculty. In this interview Ian shares more about his life and science.

Note: This episode includes Spanish language.Dr. Tricia welcomes Doris and her son to Treble Health Weston for a first in-clinic visit. Hear the patient's reaction and confidence after the first fitting. Learn why they chose Treble Health Weston for tinnitus care.Get started with Treble Health:Schedule a complimentary telehealth consultation: treble.health/free-telehealth-consultation Take the tinnitus quiz: https://treble.health/tinnitus-quiz-1Download the Ultimate Tinnitus Guide: 2024 Edition: https://treble.health/tinnitus-guide-2024

In this podcast, expert clinicians focus on increasing diversity and inclusivity in LN clinical research. They address the persistent underrepresentation of minority populations in clinical trials and its implications for equitable therapeutic access. The conversation highlights best practices for inclusive trial design, community engagement, and culturally sensitive recruitment strategies that build trust and ensure all patients benefit from scientific advancements.   To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.healio.com/cme/mededtalks/rheumatology/20251201/3inclusive-innovation

This week, a world first gene therapy treats rare Hunter syndrome. Could these personalised medicines be used more widely? We speak to Claire Booth, professor in Gene Therapy at Great Ormond Street Hospital. And high in the Chilean desert, the last bit of 13 billion year old light has hit the mirror of the Atacama Cosmology Telescope for the last time. Dr Jenifer Millard, a science communicator and host of the Awesome Astronomy podcast, tells us what it's been up to for the past 20 years.And Penny Sarchet, managing editor at New Scientist brings her pick of the latest new discoveries.Think you know space? Head to bbc.co.uk, search for BBC Inside Science, and follow the links to the Open University to try The Open University Space Quiz. Presenter: Tom Whipple Producers: Alex Mansfield, Ella Hubber, Jonathan Blackwell, Tim Dodd and Clare Salisbury Editor: Martin Smith Production Co-ordinator: Jana Bennett-Holesworth

his episode of 'Conversations in Lung Cancer Research' hosted by Dr Alex Davis, features a discussion with Dr. Laird Cameron and Dr. Annie Wong on the current state of lung cancer care and research in New Zealand. The panel explores the challenges and disparities faced by thoracic cancer patients, particularly among the indigenous Māori population. The conversation highlights the differences between patient populations in New Zealand and Australia, the impact of rurality on cancer care, the importance of clinical trials and multinational collaborations, and the future prospects for lung cancer treatments and interventions. (00:00) Introduction and Acknowledgements(01:01) Exploring Lung Cancer in New Zealand(01:13) Meet the Experts: Dr. Laird Cameron and Dr. Annie Wong(01:48) Challenges in Lung Cancer Diagnosis and Treatment(02:44) Specialisation Stories: Why Lung Cancer?(05:20) Comparing Patient Populations: New Zealand vs. Australia(07:44) Lung Cancer Care Pathways in New Zealand(09:17) Access to Treatments and Therapies(14:57) The Role of Lung Cancer Nurses(18:21) Rural Challenges in Lung Cancer Care(22:06) Radiology and Diagnostic Delays(23:08) CTDNA and Liquid Biopsy in New Zealand(25:03) Strengths and Weaknesses in Lung Cancer Care(29:29) The Impact of Clinical Trials and TOGA(33:00) Future Interventions and Wishlists(39:33) Concluding Thoughts and Farewell

Welcome back to Resiliency Radio with Dr. Jill Carnahan, where we bring you cutting-edge conversations with leading experts in longevity, regenerative medicine, and whole-body healing. In today's episode, Dr. Jill sits down with Dr. Khoshal Latifzai, a Dartmouth-trained, Yale-residency Emergency Medicine physician and co-founder of Rocky Mountain Regenerative Medicine, to explore the future of personalized healthcare. This powerful discussion dives deep into regenerative medicine, innovative longevity therapies, and the systemic challenges doctors and patients face in today's healthcare system. You'll learn how advanced treatments—like hyperbaric oxygen therapy, ozone therapy, and cellular therapies—are transforming lives, improving recovery, and helping people optimize their vitality at every stage of life.

CME credits: 0.25 Valid until: 26-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/ Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with a fear of needles, which can negatively impact patent compliance. However, the currently available oral small-molecule therapies apremilast and deucravacitinib have demonstrated lower levels of skin clearance relative to biologics for the treatment of plaque psoriasis. Investigation into novel oral small-molecule therapies is ongoing, such as next-generation TYK2 inhibitors and the first-in-class investigational targeted oral peptide icotrokinra, which selectively targets IL-23 receptor signaling. These therapies have demonstrated dramatically improved clinical responses versus comparators and may significantly impact the current treatment paradigm for plaque psoriasis. =

In this episode, Megan chats with Juniper about the unique world of providing rehabilitation for exotic animals. Juniper shares fascinating stories and practical examples from her work with species such as hedgehogs, sugar gliders, turkeys, and iguanas. Tune in to learn how rehab principles are adapted to meet the needs of these diverse and extraordinary patients.  Learn more about Juniper Connal: https://www.wcvp.co.uk/  Learn more about Paw Prosper's special offer: https://pawprosper.com/OPH Learn more about Paw Prosper: https://pawprosper.com/ To learn about Onlinepethealth, watch a free webinar, or join any of our Facebook groups, click here: https://onlinepethealth.com/podcast

Access Transcript | Access Slides | Obtain Credit | For More Information    …

As part of our 2025 Board Review Course Dr. Mahmood provides insights into the contemporary state of our understanding of CAR T therapies, their CV risk, and management. You can purchase the complete set of review course videos at the link below. This includes modules covering the Management & Detection of Cardiac Dysfunction, Toxicities of Traditional Therapies, Hematology, and Immunotherapy.https://members.ic-os.org/store/viewproduct.aspx?id=26378193

Emily Adams came into the studio to chat with Kitty and Alan. Emily is a Herbal Medicine Practitioner from Wild Root Therapies  She is island based and has a wonderful space to practice herbal medicine at Cheverton Farm , just outside Newport. For more details about Wild Root Therapies , go to www.wildroot-therapies.com or pop onto social media for latest information

Barbara Lamb isn't your everyday therapist; she's one of the world's leading pioneers in exploring humanity's most extraordinary experiences. A licensed Marriage and Family Therapist, Certified Hypnotherapist, and Regression Therapist based in California, Barbara has dedicated her career to working with individuals who claim encounters with beings not of this Earth.Since 1991, she has guided more than 550 experiencers through over 1,800 regressions into their otherworldly encounters, opening doors to hidden memories of contact with extraterrestrial visitors. Her groundbreaking methods, first shaped by the Association for Past Life Research and Therapies, set the gold standard for regression therapy in this strange and uncharted realm.Far more than a practitioner, Barbara is also a teacher and mentor to other therapists worldwide, training them to navigate the delicate and often shocking terrain of ET contact. She has taught for leading institutes and boards across the globe, sharing the skills needed to explore these cosmic frontiers of human experience.Currently serving as President of the Academy of Clinical Close Encounter Therapists and as a board member for the Journal of Abduction-Encounter Research, Barbara Lamb continues to stand at the intersection of psychology and the paranormal, pushing the boundaries of what modern therapists and modern science are willing to confront.

In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Matthew G. Bowles, PharmD, MBA, CSP, Pharmacy Clinical Team Lead with Vanderbilt Specialty Pharmacy, Vanderbilt Health, and lead author on the study “Getting to specialty treatment in dermatologic inflammatory conditions: Treatment requirements and patient journey,” published February 2025 in the Journal of Managed Care & Specialty Pharmacy. They discuss the reasons for conducting and results of the study, as well as the impacts the study may have on specialty and managed care pharmacy.

Please visit answersincme.com/PME860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) discuss strategies for optimizing the detection and management of CRSwNP, with a focus on the role of biologics in patient-centered care. Upon completion of this activity, participants should be better able to: Identify best practices to facilitate the early detection of CRSwNP; Discuss the risk-benefit profiles of approved and emerging biologics for the treatment of CRSwNP; and Identify patient-centered, multidisciplinary strategies to integrate biologics into the treatment algorithm for patients with CRSwNP.

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

Please visit answersincme.com/UPU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in managing patients with retinal vein occlusion (RVO) discusses the use of longer-acting anti-VEGF treatments for treating RVO. Upon completion of this activity, participants should be better able to: Explain the rationale for exploring longer-acting anti-VEGF treatment for patients with retinal vein occlusion (RVO); Differentiate the clinical profiles of available and emerging anti-VEGF treatments for macular edema following RVO, based on the latest evidence; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

Today we're diving into something most people never think to connect with mold or their environment… heart disease. Yep the number one cause of death in the U.S.I'm joined by Dr. John Kim, a functional medicine practitioner and the founder of Kim Wellness. Dr. Kim has an incredible story. At just 33, he had a heart attack with no classic risk factors. That experience sent him down the rabbit hole of why a “healthy” guy ends up in the ER… and that journey eventually led him straight to environmental exposures, including mold toxicity.We get into the stuff your doctor probably isn't talking about: how toxins in your home impact cholesterol production, inflammation, mitochondrial function, your immune system, and ultimately your heart. Dr. Kim breaks down how different environmental stressors stack over time and why so many people are walking around with symptoms no one is connecting back to their space.He also walks us through his six-step “Encore Method,” where he focuses on everything between lowering environmental impact, opening up detox pathways, rebuilding the microbiome, and helping the body become more resilient overall.If anything we talked about today hit home, Dr. Kim set up a really awesome #moldfinders special! He's offering a super discounted 45-minute Discovery Call to help you start digging into the hidden root causes. Check it out here! https://www.kimwellness.co/podcast-listeners-landing-page-rmoldfindersMore about Dr. John Kim:Website: drjohnkim.comInstagram: @john.pharmdEpisode Breakdown00:00 — Why we're talking about heart disease on a mold podcast01:07 — Introducing Dr. John Kim04:04 — Dr. Kim's story: a heart attack at 3306:01 — What most people misunderstand about heart disease09:25 — Where functional medicine actually shines20:13 — Light, circadian rhythm, and why sunlight matters more than you think24:14 — The environmental toxin conversation most doctors skip31:36 — How mycotoxins interfere with cholesterol synthesis33:00 — What mycotoxins do to your immune system33:37 — Why “more supplements” isn't the answer to cellular dysfunction35:32 — Therapies that truly support cellular health36:49 — Breaking down the Encore Method37:46 — The nervous system–environment connection38:29 — Diet, detox, and what actually moves the needle44:28 — The mental and emotional side no one talks about50:17 — The reality of mold remediation — and why many people struggle54:07 — What effective mold recovery really requires57:36 — Final thoughts and where to find Dr. Kim's resourcesIG: @MoldFindersNot sure the best way to get started? Follow these simple steps to hit the ground running…Step 1: Subscribe To Our Podcast!Step 2: Want a Test More Advanced Than ERMI? www.TheDustTest.com⁠Step 3: Already Have An ERMI? Find Out What It Actually Means. ⁠⁠www.ErmiCode.com⁠Step 4: Text Me (yes, it's really me!) The Mold Phone: 949-528-8704Step 5: Book A FREE Consultation www.yesweinspect.com/call

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Elevated Lipoprotein(a) or Lp(a) is increasingly recognized as a significant, independent risk enhancer for cardiovascular disease (CVD). This course explores the evolving landscape of Lp(a) in clinical practice, emphasizing the importance of Lp(a) testing in comprehensive cardiovascular risk assessment. The safety and efficacy of current and emerging lipid-lowering therapies, with a focus on novel agents targeting Lp(a) reduction will be examined.  Claim CE and MOC credits: https://bit.ly/4r1xjU6

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan TROP2 ADCS for patients with EGFR-mutated NSCLCTIGIT-targeting agents: domvanalimab, rilvegostomigPresenters:Benjamin Levy, MD, FASCOAssociate ProfessorJohns Hopkins School of MedicineClinical DirectorJohns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)Washington, DCAlex Spira, MD, PhD, FASCODirector Clinical ResearchVirginia Cancer SpecialistsCEO NEXT Oncology VirginiaFairfax, VirginiaContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/4qZLR6B Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textDr Erin Bellamy is a returning guest on our show! Be sure to check out her first appearance on episode on 732 of BBR!Dr. Erin Louise Bellamy, MHP, is the founder of Integrative Ketogenic Research and Therapies which uses principles of Metabolic Psychiatry to provide remote, highly personalized 1 on 1 metabolic therapy for both psychiatric conditions and overall metabolic health and goes as far as treating psychiatric conditions such as depression, anxiety, bipolar disorder and schizophrenia, as well as overall metabolic health.Dr. Bellamy's mission is to empower individuals with comprehensive education, expert guidance, and consistent support in the understanding and practical application of metabolic interventions, including Ketogenic Metabolic Therapy, to promote enhanced physical and mental well-being.Dr. Bellamy's approach is aimed at increasing the levels of ketones in your body, which are small molecules produced when your body breaks down fat. Ketones have been shown to protect the brain and reduce inflammation and is a method to increase mitochondria and improve metabolic health, which in turn can have positive impacts on both physical and mental well-being.Find Dr. Erin Bellamy at-TW- @IKRT_orgTW- @erinlbellamyIG- @ikrt_orghttps://www.ikrt.org/Email- hello@ikrt.orgFind Boundless Body at- myboundlessbody.com Book a session with us here!

Debating confessional confidence, removing warnings on hormone therapies, conservatives split over anti-Semitism, and Arsenio Orteza reviews Crash Rickshaw's Big Sir. Plus, record-breaking bagpipes, Cal Thomas on bringing order to Congress, and the Thursday morning newsSupport The World and Everything in It today at wng.org/donateAdditional support comes from Cedarville University—a Christ-centered, academically rigorous university located in southwest Ohio, equipping students for Gospel impact across every career and calling. Cedarville integrates a biblical worldview into every course in the more than 175 undergraduate and graduate programs students choose from. New online undergraduate degrees through Cedarville Online offer flexible and affordable education grounded in a strong Christian community that fosters both faith and learning. Learn more at cedarville.edu, and explore online programs at cedarville.edu/online.From His Words Abiding in You, a Bible memorization podcast designed for truck drivers. His Words Abiding in You … on all podcast apps.And from Asbury University's honors program. Where rigorous academics meet deep thinking and spiritual growth. asbury.edu/honors

Joel Gelfand, MD, MSCE, FAAD interviewed by Sanna Ronkainen, MD, FAAD

Please visit answersincme.com/SYV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in retinal vein occlusion (RVO) discuss diagnosis and anti-VEGF treatment of the condition. Upon completion of this activity, participants should be better able to: Explain the rationale for exploring longer-acting anti-VEGF treatment for patients with RVO; Recognize the importance of early diagnosis to address the burden of RVO; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.

The FDA recently announced it will be removing warning labels on hormone replacement therapy medications. In an exclusive conversation with Martha, Health and Human Services Secretary Robert F. Kennedy Jr. explains the FDA's decision and why these labels are now considered misleading. Later, Martha revisits her conversation with FOX News contributor and board-certified radiologist, Dr. Nicole Saphier, who explains the risks of hormone replacement therapy as a treatment for menopause and some of the common misconceptions. Learn more about your ad choices. Visit podcastchoices.com/adchoices

November 12, 2025 ~ Dr. Carrie Leff, internist and certified menopause provider at Henry Ford Health, joins Chris, Lloyd, and Jamie to discuss the efficacy of hormone therapies for menopause as the FDA is removing black box warnings about serious risks. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this moving Veterans Day episode of Ever Forward Radio, retired Air Force Lt. Col. Benjamin Forest opens up about his personal battle with depression, grief, and identity loss after 25 years of service — and how psychedelics became a catalyst for healing, love, and authentic living. He and Chase explore the mental-health crisis among veterans, the epidemic of loneliness and suppressed emotion in men, and how plant medicine, breathwork, and community can help reconnect us to meaning and purpose. Forest shares insights from his book Trip of a Lifetime: The Psychedelic Guide to Healing, Loving & Living, explaining that true recovery requires vulnerability, relational healing, and learning to open the heart — whether through psychedelics or other integrative practices. Follow Ben @benjamin.forest.bliss Follow Chase @chase_chewning ----- 00:00 – Introduction & U.S. mental-health statistics 02:22 – A cultural depression: loneliness, disconnection & anxiety 04:29 – Playing a role vs. discovering the authentic self 07:07 – The military, identity, and emotional suppression 10:30 – Masculinity, vulnerability, and the loneliness epidemic 13:00 – Grief, alcohol, and the cost of unprocessed emotion 15:30 – Healthy masculinity and belonging after service 18:00 – The biology of belonging & the need for community 20:10 – Losing identity and brotherhood after leaving the military 23:10 – Lessons learned from 25 years in uniform 24:30 – Healing, loving, and living: wounds and relational repair 27:30 – Learning to love well and open the heart 28:45 – Doing life "right" and rediscovering joy 31:00 – Psychedelics as heart-openers & catalysts for healing 34:30 – Veterans leading the way for psychedelic legalization 38:40 – Alternatives to psychedelics: breathwork & somatic therapy 44:00 – Integration: applying lessons after the trip 46:50 – The danger of ego, money, and misuse in plant-medicine circles 49:50 – Writing Trip of a Lifetime and lessons learned 54:30 – Advice to young service members: asking for help is strength 56:16 – What "Ever Forward" means to Benjamin Forest ----- Episode resources: Watch and subscribe on YouTube Learn more about Benjamin

The FDA's move to remove ‘Black Box' warnings on hormone therapy prescriptions could provide help for women during menopause. The warnings appeared after a concerning study, and resulted in many women not proceeding with prescribed therapies. But the warnings dealt with products not prescribed now. The history of the use of ‘equine estrogen' vs today's recommended products and other available products, with local physician Dr. John Littel.

Send us a textJoin Dr. Daphna Yasova Barbeau as she kicks off The Incubator's live coverage from the Children's Hospitals Neonatal Consortium (CHNC) 2025 Symposium in Denver. This opening episode sets the stage for two days of conversations focused on improving care for high-risk infants through data sharing, collaboration, and quality improvement across Level IV NICUs. Daphna introduces the mission behind CHNC and its powerful Children's Hospitals Neonatal Database (CHND)—a resource driving benchmarking and innovation nationwide. Tune in for context, purpose, and the energy that fuels this year's meeting before diving into interviews with CHNC leaders and attendeesSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

CardioNerds kicks off its advanced therapies series with Chair of the CardioNerds Heart Failure Council, Dr. Jenna Skowronski, co-chair of the series, Dr. Shazli Khan, and Episode FIT lead, Dr. Jason Feinman. In this first episode, they discuss the process of advanced therapies evaluation with Dr. Michelle Kittleson, Professor of Medicine and Director of Education in Heart Failure and Transplantation at Cedars-Sinai. In this case-based discussion, they cover the signs and symptoms of end-stage heart failure, the initial management strategies, and the diagnostic workup required when considering advanced therapies. Importantly, they discuss the special considerations for pursuing left-ventricular assist device (LVAD) versus heart transplantation as well as the multidisciplinary, team-based approach needed when advanced therapies are indicated.  Notes were drafted by Dr. Shazli Khan.  Audio editing for this episode was performed by CardioNerds Intern, Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Guideline-directed medical therapy (GDMT) is indicated in all heart failure patients and improves survival, but progressive symptoms and intolerance to GDMT can be warning signs of disease progression. The I-NEED-HELP mnemonic is an excellent reference when considering referral for advanced therapies (Figure).   Management of acute decompensation includes diuretics and possible inotropic support. The inotropic agent used should be whichever best suits your specific patient. Milrinone may result in more hypotension, whereas dobutamine may result in more tachycardia. Tachycardic and normotensive patients may do better with milrinone, while hypotensive patients with normal heart rates may do better with dobutamine. Notably, DoReMi found no difference between milrinone and dobutamine for patients with cardiogenic shock.  The initial diagnostic evaluation includes an echocardiogram, right heart catheterization (RHC), and often cardiopulmonary exercise testing (CPET) to objectively assess the status of the heart. Comprehensive labs, imaging and cancer screening are also needed to assess all other organs.   When making the decision to pursue advanced therapies, always ask:   Is the heart sick enough?   Is the rest of the body well enough?   These two questions provide a framework to guide if patients are optimal candidates for transplant versus LVAD.   The advanced therapies evaluation is a team sport! Patients will meet not only with advanced heart failure cardiologists, but also cardiac surgeons, psychiatrists, social workers, nutritionists and pharmacists. All team members are of critical value in the process.   Notes 1.) What are the key features of advanced cardiomyopathy, and when should providers consider referral for advanced therapies?   Advanced cardiomyopathy may present as recurrent hospitalizations for decompensated heart failure, intolerance to GDMT with symptomatic orthostasis and hypotension, and progressive symptoms of heart failure despite medical therapy.   The I-NEED-HELP mnemonic is a helpful tool to identify patients at risk of heart failure and is defined as follows: Need for Inotropic support, New York Heart Association (NYHA) Class IV symptoms, End-Organ Dysfunction, Ejection fraction

Prostate cancer is one of the most common cancers in men. While treatment options have improved, advanced stages of the disease remain difficult to manage. One promising approach involves a process called ferroptosis. This is a type of programmed cell death that relies on iron and lipid oxidation to kill cancer cells by damaging specific fats in their outer membrane. These fats are especially vulnerable in environments with normal oxygen levels. However, many prostate tumors grow in low-oxygen areas of the body, a condition known as hypoxia, where ferroptosis becomes less effective. A recent study, titled “Hypoxia induced lipid droplet accumulation promotes resistance to ferroptosis in prostate cancer,” and published on Oncotarget (Volume 16), explores how oxygen-poor environments help prostate cancer cells resist treatment and what strategies could help overcome this resistance. Full blog - https://www.oncotarget.org/2025/11/06/how-low-oxygen-shields-prostate-cancer-from-ferroptosis-therapies/ Paper DOI - https://doi.org/10.18632/oncotarget.28750 Correspondence to - Noel A. Warfel - warfelna@arizona.edu, and Shailender S. Chauhan - shailenderc@arizona.edu Abstract video - https://www.youtube.com/watch?v=xFypDT4ALmc Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28750 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, hypoxia, lipid droplets, ferroptosis, resistance, prostate To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Download the transcript here

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Listen to the podcast here

Please visit answersincme.com/XCG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. This educational activity brings together leading experts in ophthalmology and oncology to explore clinical strategies for managing ocular adverse events associated with a novel class of therapies for advanced breast cancer: the oral selective estrogen receptor degraders (SERDs). Faculty will share key insights and practical guidance on identifying and managing common ocular side effects—particularly photopsia and dry eye—with the goal of enhancing patient care and improving quality of life for individuals navigating survivorship with advanced breast cancer. Upon completion of this activity, participants should be better able to: Recognize the implications of using oral SERDs in HR-positive, HER2-negative breast cancer for ophthalmic practice; Describe the ocular toxicities associated with oral SERDs used in breast cancer treatment; and Apply multidisciplinary strategies to facilitate the detection and management of ocular toxicities in patients receiving oral SERDs.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of groundbreaking advancements and strategic collaborations that promise to transform drug development and patient care.In the autoimmune space, Boehringer Ingelheim has made a significant move by securing a $570 million agreement with CDR-Life. This deal centers on a trispecific antibody, a novel therapeutic approach that targets multiple pathways simultaneously, potentially revolutionizing treatments for autoimmune diseases. Boehringer's commitment to these cutting-edge modalities highlights their strategy to leverage novel technologies for more effective therapeutic solutions.Similarly, Celltrion has entered a $744 million collaboration with Kaigene, focusing on two preclinical autoimmune drugs. This partnership marks Celltrion's strategic shift from biosimilars to novel biologics, positioning the company at the forefront of biologic therapeutics. By investing in early-stage research, Celltrion aims to introduce transformative therapies for autoimmune conditions, showcasing the industry's willingness to bet on groundbreaking scientific advancements.In gene editing, Azalea Therapeutics is gaining attention with its focus on permanent genome editing using a dual-vector approach. Backed by $82 million in funding and support from CRISPR pioneer Jennifer Doudna, Azalea is poised to develop potentially curative solutions through single-dose treatments. The credibility lent by a Nobel laureate adds anticipation to their research outcomes, with the potential to significantly impact gene therapy.Shifting focus to clinical trials, Sarepta Therapeutics faces challenges after missing the primary endpoint in its confirmatory trial for Duchenne muscular dystrophy drugs. Despite this setback, Sarepta is pursuing full FDA approval, emphasizing the complex interplay between clinical data and regulatory strategies. This situation underscores the critical importance of robust confirmatory trials in securing drug approvals and ensuring patient access to new therapies.Merck is making strategic moves in oncology by regaining full control over an early-phase asset and securing $700 million from Blackstone for its oncology pipeline. This dual focus on asset acquisition and financial fortification reflects Merck's aggressive growth strategy aimed at expanding its cancer treatment offerings.Emerging from stealth mode, Neok Bio has secured a $75 million investment to advance bispecific antibody-drug conjugates into clinical trials. These bispecific ADCs represent the forefront of targeted cancer therapies, aiming for precision targeting of cancer cells while minimizing off-target effects. Neok Bio's progress could significantly enhance oncology treatment paradigms through improved therapeutic indices.Turning to regulatory landscapes, Teva's recall of over half-a-million bottles of prazosin hydrochloride due to potential carcinogenic impurities highlights ongoing challenges in ensuring drug safety and quality control within manufacturing processes. Such recalls underscore the critical importance of maintaining high standards in pharmaceutical production.In broader industry developments, we see dynamic trends where scientific innovation meets strategic business decisions and regulatory considerations. The potential impact on patient care is profound, with breakthroughs in autoimmune treatments, gene editing technologies, and targeted cancer therapies poised to alter therapeutic landscapes significantly.UCB has achieved another milestone with FDA approval for Kygevvi, an ultra-rare disease medication marking their third approval in rare conditions within three years. This success underscores UCB's strategic focus on niche markets that offer less competition but significant patient impact. Advancements in genetic research aSupport the show

Here's a polished podcast blurb suitable for LinkedIn, BlueSky, or Apple Podcasts listings — written in the JIMD Podcast tone and style: ⸻ It's one of the most talked-about breakthroughs of 2025, a first-in-human demonstration of in vivo gene editing to treat an inherited metabolic disease. In this episode, Kiran Musunuru and Rebecca Ahrens-Nicklas are joined by Julien Baruteau to unpack what this means for the field. They explore the science behind gene editing, the importance of ethical design, and the emotional weight of stopping therapy once enzyme function is restored. The conversation bridges the NEJM landmark paper (Musunuru et al., 2025) and the accompanying JIMD editorial (Rahman & Baruteau, 2025), reflecting on what this moment tells us about the future of metabolic medicine and how ready we are for it. First in Human Gene Editing for an Inherited Metabolic Disease Shamima Rahman, Julien Baruteau https://doi.org/10.1002/jimd.70056 Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease Kiran Musunuru, et al https://www.nejm.org/doi/10.1056/NEJMoa2504747

Research is more than just finding interesting stats. It's about finding better ways to deliver savings, simplicity, and support. In this episode, you'll hear from managed care pharmacy researchers who are doing just that, delivering data driven insights to drive affordability and access in health care.  Pat Gleason, PharmD, BCPS, FCCP, FAMCP, assistant vice president of health outcomes; Nick Friedlander, PharmD, clinical program pharmacist; and Simone Ndujiuba, PharmD, BCOP, clinical oncology pharmacist senior principal; and host Alex Cook, senior public relations manager, discuss how Prime's research helps address affordability and accessibility issues and guides health care providers and peers toward clarity on treatment for complex health conditions. Research topics covered:Three-Year Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists Among Commercially Insured Adults with Obesity without Diabetes Trends in Real-World Persistence to Weight Loss Glucagon-Like Peptide-1 Receptor Agonists from 2021 to 2024 Among Commercially Insured Adults without Diabetes — This study earned a platinum award from AMCP.  Impact of a Medical Claims Automated Glucagon Like Peptide-1 Drugs Prior Authorization Program— This study earned a gold award from AMCP.Validation of Long-term Savings from a Pharmacist-to-Prescriber Telephonic Intervention — This study earned a gold award from AMCP. Total Cost of Care and Adverse Effects Assessment of Bispecific T-cell Engagers and Chimeric Antigen Receptor T-cell Therapies for Relapsed Refractory Follicular Lymphoma  -------------------------Content in this podcast is for informational or educational purposes only.The content also does not substitute professional medical advice or consultations with health care professionals. Always seek advice from a physician or other health care providers with any questions you have regarding a medical treatment or condition before undertaking a new health care regimen.

Are you secretly running on anxiety, even as everyone praises your productivity, drive, and ability to “do it all”? I'm joined by an award-winning psychologist, Dr. Lalitaa Suglani, who breaks down the difference between being simply driven and silently battling high-functioning anxiety—a line so thin, most of us don't even realize we've crossed it.We'll dive deep into what high-functioning anxiety really is, how it hides behind ambition, and why so many busy, successful women are silently caught in its grip. Dr. Lalitaa reveals how childhood patterns might still be running the show, why saying “yes” is sometimes a sign you're feeling “not enough,” and how external success can actually keep you stuck in survival mode. You'll find out what high-functioning anxiety really looks like from the inside out, how it might be showing up in your body, and the practical next steps to help you break free from the overwhelming cycle without sacrificing your ambition or success. By the end of the episode, you'll have the tools to start drawing boundaries and understanding your triggers so you can stay ambitious without the constant wave of stress, guilt, or shame. Hit play and let's dive in.4:53 – What High Functioning Anxiety Really Looks Like for High Achievers11:02 – How Childhood Experiences Shape Adult Anxiety 18:58 – How to Spot the Difference Between Being Driven or Overwhelmed and the External Red Flags of High-Functioning Anxiety 24:11 – The First Real Step to Feeling Better (It's NOT Just Slowing Down)28:57 – The Tools and Therapies that Actually Help and How to Find Support32:36 – What Life After Healing From High-Functioning Anxiety Can Look Like Episode Links:Connect with Dr. Lalitaa: Website | InstagramGrab Dr. Lalitaa's book on High-Functioning Anxiety